Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD

Lindsay M. Wallace,1 Nizar Y. Saad,1 Nettie K. Pyne,1 Allison M. Fowler,1 Jocelyn O. Eidahl,1 Jacqueline S. Domire,1,5 Danielle A. Griffin,1 Adam C. Herman,4 Zarife Sahenk,1,2,3 Louise R. Rodino-Klapac,1,2 and Scott Q. Harper1,2

1Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA; 2Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA; 3Department of Neurology, The Ohio State University College of Medicine, Columbus, OH, USA; 4Research Information Solutions and Innovation Infrastructure, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA

RNAi emerged as a prospective molecular therapy nearly 15 years ago. Since then, two major RNAi platforms have been under development: oligonucleotides and gene therapy. Oligonucleotide-based approaches have seen more advancement, with some promising therapies that may soon reach market. In contrast, vector-based approaches for RNAi therapy have remained largely in the pre-clinical realm, with limited clinical safety and efficacy data to date. We are developing a gene therapy approach to treat the autosomal-dominant disorder facioscapulohumeral muscular dystrophy. Our strategy involves silencing the myotoxic gene DUX4 using adeno-associated viral vectors to deliver targeted microRNA expression cassettes (miDUX4s). We previously demonstrated proof of concept for this approach in mice, and we are now taking additional steps here to assess safety issues related to miDUX4 overexpression and sequence-specific off-target silencing. In this study, we describe improvements in vector design and expansion of our miDUX4 sequence repertoire and report differential toxicity elicited by two miDUX4 sequences, of which one was toxic and the other was not. This study provides important data to help advance our goal of translating RNAi gene therapy for facioscapulohumeral muscular dystrophy.

INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal-dominant genetic condition with an estimated incidence of 1 in 8,333 to 1 in 20,000 people.1–3 FSHD was initially classified on the basis of a general pattern of wasting and weakness in muscles of the face, shoulder-girdle, and arms. However, it is now clear that the classical picture of muscle involvement in FSHD is not universal, as some patients may have only limited muscle pathology, whereas others can develop asymmetrical or bilateral weakness in lower limbs, abdominal muscles, and the diaphragm.6,7 Likewise, there is variability in age at onset, rate of progression, and severity of weakness among individuals within the FSHD community. As a result, some patients may maintain lifelong ambulation, whereas others require wheelchair and caregiver assistance.7

In addition to this complicated clinical picture, the molecular mechanisms underlying FSHD are also complex and required decades of investigation to decipher. Great gains in knowledge were achieved in the past decade especially, and the field has focused largely on a model in which de-repression of the DUX4 gene is a primary insult in muscles of FSHD patients.8–13 The identification of DUX4 as a target gene provided a platform to finally enable translational research on FSHD, by allowing the development of DUX4-expressing animal models and DUX4-targeted molecular therapies.13–21

Our laboratory has been working to develop an RNAi-based gene therapy approach to silence the DUX4 gene as a putative treatment for FSHD.20 Specifically, we designed single-stranded adeno-associated viral (AAV) vectors carrying U6 promoter-driven artificial microRNAs targeting the DUX4 mRNA (called miDUX4s). The antisense guide-strands of our miDUX4 constructs contained perfect complementarity with DUX4 across a 22 nt stretch of sequence, thereby directing the transcript toward an RNAi degradation pathway. In a proof-of-concept study using human cells and mouse muscles overexpressing DUX4, we identified a lead sequence, called miDUX4.405 (or mi405), that significantly reduced DUX4 protein and mRNA and improved muscle damage phenotypes associated with large quantities of DUX4 in mice.20 With an overall goal of translating RNAi therapy for FSHD, in this study our aims were to improve our first-generation miDUX4 vectors, expand the repertoire of sequence options that could be useful for targeting DUX4, and safety test our lead sequences in mice and human cells, prior to performing a more expensive good laboratory practice (GLP) toxicology study.

Received 7 November 2017; accepted 19 December 2017; https://doi.org/10.1016/j.omtm.2017.12.005.

Correspondence: Scott Q. Harper, PhD, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, 700 Children’s Drive, Room WA3015, Columbus, OH, 43205, USA.
E-mail: scott.harper@nationwidechildrens.org
RESULTS

We previously designed and validated five miRNAs targeting DUX4.20 Among this first batch, miDUX4.405 (mi405) performed the best and became our lead sequence. However, as RNAi-based gene therapy is still an emerging field with limited safety data, we wanted to ensure that we had backup sequences that could also be translated toward clinical application in the event of unforeseen mi405 toxicity.22–24 With that goal in mind, we developed a simple algorithm to select additional miDUX4 sequences. New miDUX4s were designed using the following criteria: 22 nt mature miRNA length, perfect antisense complementarity to the human DUX4 mRNA, <60% GC content of the mature duplex, and guide-strand biasing, such that the last 4 nucleotides of the antisense 5’ end were A:U rich, and the last 4 nucleotides of the antisense 3’ end were G:C rich. Filtering the DUX4 gene using these criteria produced 34 new candidates, for a total of 39 miDUX4 sequences tested overall (Figure 1A; Table S1). We cloned each new sequence into a U6 expression plasmid and then performed in vitro gene silencing screens in HEK293 cells using a dual luciferase assay in which the DUX4 cDNA was cloned as the 3’ UTR of Renilla luciferase, and
By using a similar strategy, by demonstrating proof of principle for the disease animal models, followed later by dose escalation safety testing studies involved historically, the template for performing pre-clinical gene therapy in vitro of our miDUX4 sequences produced >50% DUX4 silencing using feasibly test them (Figure 1D). We noted that roughly three-quarters being tested in ongoing work or reserved as backups until we can further.

mi1434, mi1445, and mi1520). Of these, for practical reasons (time and funding) we selected 2 as our leads (mi1155 and mi405) for further in vivo testing in this study, with the additional miDUX4s being tested in ongoing work or reserved as backups until we can feasibly test them (Figure 1D). We noted that roughly three-quarters of our miDUX4 sequences produced >50% DUX4 silencing using in vitro assays, thereby validating our miRNA design strategy.

Historically, the template for performing pre-clinical gene therapy studies involved first demonstrating efficacy for a given strategy in disease animal models, followed later by dose escalation safety testing in wild-type animals. Indeed, we began this work several years ago using a similar strategy, by demonstrating proof of principle for the efficacy of RNAi therapy for FSHD targeting DUX4 in mice. Using a first-generation AAV vector system, we showed that the U6.mi405, we identified 11 miD- UX4s (28% of all tested) with >75% silencing using both metrics (mi182, mi185, mi187, mi333, mi334, mi405, mi407, mi1155, mi1434, mi1445, and mi1520). Of these, for practical reasons (time and funding) we selected 2 as our leads (mi1155 and mi405) for further in vivo testing in this study, with the additional miDUX4s being tested in ongoing work or reserved as backups until we can feasibly test them (Figure 1D). We noted that roughly three-quarters of our miDUX4 sequences produced >50% DUX4 silencing using in vitro assays, thereby validating our miRNA design strategy.

Table 1. AAV Vector Doses, Routes of Administration, and Time Points Used in This Study

<table>
<thead>
<tr>
<th>Total Particles</th>
<th>vg/kg</th>
<th>Time Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intramuscular Delivery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 x 10^10</td>
<td>8.5 x 10^13</td>
<td>2 weeks, 8 weeks</td>
</tr>
<tr>
<td>1 x 10^11</td>
<td>4.6 x 10^13</td>
<td>2 weeks, 8 weeks</td>
</tr>
<tr>
<td>5 x 10^11</td>
<td>2.0 x 10^13</td>
<td>2 weeks, 8 weeks</td>
</tr>
<tr>
<td>1.5 x 10^12</td>
<td>6.5 x 10^13</td>
<td>2 weeks, 8 weeks</td>
</tr>
<tr>
<td>Intravascular Delivery (ILP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 x 10^10</td>
<td>1.6 x 10^12</td>
<td>3 weeks, 5 months</td>
</tr>
<tr>
<td>1 x 10^11</td>
<td>5.6 x 10^12</td>
<td>3, 6, 12 weeks; 5 months</td>
</tr>
<tr>
<td>1.5 x 10^12</td>
<td>8.0 x 10^13</td>
<td>3 weeks, 5 months</td>
</tr>
</tbody>
</table>

*Vector genomes per kilogram of muscle weight.

Using both delivery methods, we found histological evidence for dose-dependent muscle toxicity in scAAV.mi1155-treated animals (Figure 2). In particular, escalating i.m. vector doses caused increased amounts of regenerated myofibers (indicated by centrally located myonuclei in H&E-stained cryosections), demonstrating that muscles had been damaged and were subsequently repaired in the 8 weeks prior to this time point (Figure 2A). Lower, clinically relevant doses appeared normal (2 x 10^10 particles) to relatively normal (1 x 10^11 particles) histologically at this time point. Artificially shaded areas (purple) on whole-muscle composite images show the extent of muscle regeneration (Figure 2A). Similar to our i.m. results, animals that received low-dose (3 x 10^10 particles) scAAV.mi1155 via ILP injection showed no overt histological evidence of muscle damage at either time point (Figure 2B). Interestingly, muscle injected with high-dose scAAV.mi1155 (1.5 x 10^12 particles) appeared normal at 3 weeks but showed widespread regeneration by 5 months, indicating a temporal component to mi1155 toxicity. Besides muscle, mi1155-treated mice showed cellular infiltrates with occasional hepatocellular single-cell necrosis in the liver, but this finding was also present in the controls and considered part of the strain background. Otherwise, no
muscles, regardless of dose or time point (Figure 3B). Because the delivery appeared histologically indistinguishable from saline-treated mice injected in humans i.m. Muscles treated with mi405 using i.v. doses, mi405-treated muscles were histologically normal at clinically relevant dose range used in previous muscle gene therapy clinical trials. (B) Photomicrographs of adult mouse TA muscles 3 weeks (top) or 5 months (bottom) after vascular delivery of scAAV.mi1155, with the indicated doses of vector. Myofibers with central nuclei, indicating muscle damage and regeneration, were abundant in the 5-month high-dose muscles, as seen in the bottom-right high-power image and visualized in the purple overlay areas of the low-powered photomicrograph. Scale bars, 50 μm for high-power; 500 μm for low-power images.

![Figure 2. In Vivo Dose Escalation of scAAV.mi1155 in Wild-Type Mice](image)

We next addressed the potential of mi405 or mi1155 to cause unintended, sequence-specific silencing of non-target genes (i.e., sequence-specific off-target effects). We are interested in translating this potential gene therapy approach to human muscles, so we performed this experiment in human muscle cell lines. To do this, we transfected normal, DUX4-negative human myoblasts with AAV proviral plasmids expressing mi405, mi1155, or a control plasmid and then performed RNA sequencing (RNA-seq) to assess gene expression changes. Surprisingly few genes were significantly changed, with only five and seven transcripts reduced >2-fold in mi1155- and mi405-treated cells, respectively (Table 2). Interestingly, three transcripts (PDGERL, LAMP3, and C1QTNF1) were changed in response to both miDUX4s, despite the fact that mi405 and mi1155 bind completely different regions of the DUX4 transcript and have different seed matches. This suggested their downregulation did not occur through a sequence-specific mechanism. Nevertheless, we queried the sequences of each downregulated transcript identified by RNA-seq against our mi405 and/or mi1155 guide and passenger strands using two different algorithms, siSPOTR and PITTA, to identify potential seed match binding sites.

![Figure 2. In Vivo Dose Escalation of scAAV.mi1155 in Wild-Type Mice](image)

In contrast to the mi1155 sequence, scAAV.mi405 was generally well tolerated following either route of administration. At clinically relevant i.m. doses, mi405-treated muscles were histologically normal relative to saline-injected muscles (Figure 3A). We did note a comparatively larger area of mouse TA muscle with central nuclei at the two highest doses, but even these levels were relatively safe compared with the damage seen in mi1155-treated muscles, and we note that the amount of vector we delivered in the two high-dose groups has never been injected in humans i.m. Muscles treated with mi405 using i.v. delivery appeared histologically indistinguishable from saline-treated muscles, regardless of dose or time point (Figure 3B). Because the scAAV.mi405-treated muscles showed little to no pathology, we wanted to ensure that the vector was expressing mi405 as expected and therefore developed an adaptor-based TaqMan assay to detect the mature mi405 sequence in vivo. Importantly, mi405 was detected in all treated muscles, and its expression increased with increasing scAAV.mi405 doses, by both i.m. and ILP delivery routes (Figure 3).

As was the case for mi1155-treated animals, mi405-treated mice also showed cellular infiltrates with occasional hepatocellular single-cell necrosis in the liver, but this finding was also present in the controls and considered part of the strain background. Otherwise, no obvious organ pathology was observed in any of the scAAV.mi405-treated animals (Supplemental Results).

![Figure 2. In Vivo Dose Escalation of scAAV.mi1155 in Wild-Type Mice](image)
DISCUSSION

The discovery of RNAi ushered in a new era of molecular biology and expanded the field of gene therapy to include gene-silencing strategies for dominant genetic diseases and viral pathogenesis.20,34,43 Perhaps not surprisingly, there was early enthusiasm about RNAi as a potentially revolutionary molecular therapy, followed by the realization that developing new technologies into market-ready treatments is typically not an overnight venture. Today, 16 years after RNAi was first described in mammalian cells, RNAi-based treatments are still experimental, although the first RNAi-based commercial products using oligonucleotide drugs, RNAi-based gene therapies using AAV vectors are still emerging, and most are still in pre-clinical stages.20,34,36,38,39,43 ClinicalTrials.gov lists only two clinical trials to date that were designed to test the safety of delivering inhibitory RNAs from AAV vectors in human beings, and both were targeting hepatitis viruses in the liver (ClinicalTrials.gov identifiers NCT01899092 and NCT02315638).40,49,50 Importantly, no adverse events have been reported, and although they represent an excellent start for the RNAi gene therapy field, safety data regarding long-term expression of inhibitory RNAs from AAV vectors remains limited. For this reason, we focused primarily on safety here, before performing an extensive pre-clinical efficacy assessment using our second-generation vectors (Figure 1).

In this study, we were interested in further developing a gene therapy approach to target the DUX4 gene using AAV and RNAi, as a prospective treatment for the dominant muscle disease FSHD. Our major aim here was to identify our lead DUX4-targeted miRNA sequences (called miDUX4s) and test the safety of our system with respect to miDUX4 overexpression in mammalian muscle (our target tissue for this therapy) and the potential reduction of non-DUX4, off-target genes in human muscle cell lines. Because mice and humans have homologous miRNA biogenesis and gene-silencing machinery, mouse models are useful for testing the safety impacts of miDUX4 overexpression in muscle. However, for the sequence-specific off-targeting experiment, we tested the potential off-target impacts of miDUX4 sequences in human cells because we ultimately want to apply this system to human gene therapy, and mice and humans have different transcriptomes. Of the two sequences we safety-tested, mi1155 was overtly toxic to muscle, whereas mi405 was not when delivered at clinically relevant doses. The fact that the low-dose mi1155 sequences were well tolerated at early time points but eventually caused whole-scale muscle turnover suggested that the toxic effects were related to accumulation of the mi1155 product over time. We are uncertain about a mechanism to explain this differential toxicity between mi1155 and mi405 on the basis of our current data. Both miRNAs were generated using identical design rules, each was expressed from the identical U6 promoter cloned into the same site within the same AAV vector system, and each was delivered to inbred C57BL/6 mice using identical routes of administration. Expressing either sequence in human cells caused surprisingly few gene expression changes, and the few transcripts that showed significant changes were reduced only 2-fold and did not seem to be targets of either strand of the mature mi405 or mi1155 sequence on the basis of our molecular beacon-binding assays (Figure 4; Table 2). Because we did not measure the impacts of mi1155 on mouse-specific transcripts, it is possible that the mi1155 sequence caused significant off-target reduction of a transcript required for healthy mouse muscle in vivo and that this hypothetical off-target silencing could have contributed.
to the muscle damage evident in mi1155-treated animals. However, because the mi405 sequence was non-toxic at clinically relevant doses and showed no significant off-targeting in human muscle cells, we decided to simply discard the mi1155 sequence for future use and focus on translating the mi405 sequence. In addition, in the future we will perform similar safety studies for other high-performing miDUX4 sequences (Figures 1 and S1).

Because of the limited safety profile of RNAi-based gene therapy vectors and the difficulty to predict which sequences will be tolerated well and which will not, we propose that our results underscore the importance of performing a toxicology screen at early pre-clinical stages, using research-grade vectors produced under non-GLP conditions. Lead candidates that pass this initial safety test can then proceed to investigational new drug (IND)-enabling toxicology assessments in mice and perhaps larger animal models, as well as scaled for production in a good manufacturing practice (GMP) vector-manufacturing facility. We believe that this strategy will ultimately save time and money as we and others work to translate RNAi-based gene therapies toward clinical application. Toward this end, we could envision the first FSHD-directed AAV-RNAi clinical trial involving direct i.m. injection to a single muscle or potentially using a vascular approach, because more gene therapy studies are moving toward this route of delivery. Other issues that need to be addressed include establishment of the AAV serotype to use for miDUX4 delivery, inclusion and exclusion criteria for patient recruitment, defining outcome measures, and of course clinical vector production issues. As we begin approaching this milestone, it will be critical to engage with regulatory bodies and clinical experts in FSHD and neuromuscular disease gene therapy to design a prospective future trial involving AAV-delivered mi405, as well as other lead candidates that emerge through the pipeline we are establishing here.

## MATERIALS AND METHODS

### Sequence Generation and Cloning of miDUXs

The Harper miRNA shuttle predictor version 1.0 was created and written in Java, enabling use of the application on Mac OS X and Windows machines. In the application, the user inputs the DNA sequence of a gene of interest, allowing the program to systematically look at 22 characters in a row beginning with the first input nucleotide and subsequently screening the entire sequence moving one character at a time. A potential 22 nt miRNA must meet three criteria to be included in the output file: (1) the first four characters must be at least 75% G and C, (2) the last four characters must be at least 75% A and U, and (3) the entire string of characters must be at least 40% A and U. The output file is a compilation of all these sequences in text file format. For DUX4, the predictor identified 44 new candidate miDUX4s (Table S1). All miDUX4s were cloned into the mir-30-based/U6 construct, as previously described. Ten miDUX4s were removed from analysis because of binding disruption from the V5 tag (mi1253, mi1254, and mi1267) or excluded sequence from the 3′ UTR (mi1552, mi1553, mi1554, mi1555, mi1557, mi1558, and mi1559). This program does not exclude sequences containing a run of four or more T nucleotides. Such sequences would be problematic if using a U6 or other RNA pol III promoter, which uses a terminator signal of four or five T's. However, RNA pol II promoters could express miRNAs containing these poly-T regions.

### Luciferase Assay

The dual luciferase reporter plasmid was modified from Psicheck2 (Promega) with a firefly luciferase cassette serving as a transfection control and the human DUX4 gene (coding region plus 3′ UTR including introns) cloned downstream of the Renilla luciferase stop codon, serving as a 3′ UTR. HEK293 cells were co-transfected (Lipofectamine 2000; Invitrogen) with the luciferase DUX4 reporter and individual U6.microRNA expression plasmids in a 1:5 molar ratio. DUX4 gene silencing was determined as previously described. Triplicate data were averaged per experiment and individual experiments performed two to four times. Results were reported as the average ratio of Renilla to firefly luciferase activity ± SD for all combined experiments.

### Western Blots

HEK293 cells were co-transfected (Lipofectamine 2000) with a CMV.DUX4.V5 expression vector containing the DUX4 3′ UTR and U6.miDUX4s or control U6.miLacZ in a 1:5 molar ratio. Protein was extracted in M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) 24 hr later and quantified using the DC Protein Assay (Bio-Rad). Fifteen microgram samples were separated on 12% SDS-PAGE, transferred to nitrocellulose membrane, and incubated with the following antibodies: mouse monoclonal antibody to V5 (horseradish peroxidase [HRP]-coupled) (1:5,000, R961-25; Invitrogen); mouse monoclonal GAPDH antibody (1:1,000, CB1001; Millipore), or goat polyclonal GAPDH (1:500, ab9483;}

---

**Table 2. RNA-Seq Gene Expression Changes in Human Myoblasts Expressing mi405 or mi1155**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Fold Change</th>
<th>p Value</th>
<th>sSiPOTr</th>
<th>PITA</th>
<th>sSiPOTr</th>
<th>PITA</th>
</tr>
</thead>
<tbody>
<tr>
<td>mi1155</td>
<td>–2.29</td>
<td>8.2e-05</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PdGFRl</td>
<td>–2.16</td>
<td>1.4e-06</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>BRC3</td>
<td>–2.11</td>
<td>1.6e-04</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>LAMP3</td>
<td>–2.11</td>
<td>1.6e-04</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CQTNF1</td>
<td>–2.11</td>
<td>1.6e-04</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>GPB4</td>
<td>–2.00</td>
<td>9.7e-06</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>mi405</td>
<td>–2.61</td>
<td>1.2e-05</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CXCL11</td>
<td>–2.46</td>
<td>1.2e-05</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>PdGFRl</td>
<td>–2.42</td>
<td>3.5e-05</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SERPINA3</td>
<td>–2.13</td>
<td>1.9e-03</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CQTNF1</td>
<td>–2.04</td>
<td>1.9e-03</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>LOC105375913</td>
<td>–2.03</td>
<td>6.0e-03</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>IL32</td>
<td>–2.02</td>
<td>7.2e-03</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>
Abcam) overnight at 4°C. GAPDH-probed blots were washed and then incubated with HRP-coupled goat anti-mouse or HRP-coupled donkey anti-goat secondary antibody (1:100,000, 115-035-003 and 705-035-147; Jackson ImmunoResearch) for 1 hr at room temperature. Following washes, blots were developed using Immobilon Western HRP substrate (Millipore) and exposed to film. DUX4.V5 quantification was assessed using ImageJ.

AAV Vector Delivery to Mice

For the bioactivity and i.m. dose escalation studies, 6- to 9-week-old C57BL/6 male and female mice received direct 40 μL i.m. injections into the TA. Bioactivity mice received adeno-associated virus AAV6.CMV.DUX4.V5 at 3 × 10^10 DNase-resistant particles (DRP) and a contralateral co-injection of AAV6.CMV.DUX4.V5 at 3 × 10^9 and either scAAV6.U6.mi405 or scAAV6.U6.mi1155 at 3 × 10^10 and 1 × 10^11 DRP. Muscles were harvested 2 weeks post-injection. N = 6 mice per vector. I.m. dose escalation mice received either saline control or scAAV6.U6.mi405 or scAAV6.U6.mi1155 at 2 × 10^10, 1 × 10^11, 5 × 10^11, or 1.5 × 10^12 DRP. Injections were delivered bilaterally and harvested 2 or 8 weeks post-injection. N = 6 legs per dose per time point. For vascular delivery, ILPs were performed on 5- to 6-week-old C57BL/6 male mice as previously described.28

Figure 4. mi405 and mi1155 Bind Specifically to Cognate Target Sites but Not Off-Target Sites

(A) A fluorescence-based molecular beacon assay was used to determine mi405 and mi1155 binding to DUX4 sequences and putative off-targets. By default, the molecular beacon folds into a stem loop structure that brings a quencher (zenBHQ) in close proximity to a fluorophore (6FAM), thereby quenching the fluorescence emission of 6FAM. We designed molecular beacons encompassing the mature sequences of mi405 and mi1155 in their loop sequence. The hybridization of the molecular beacon to a complementary sequence (represented here by a target site) separates the fluorophore and quencher, allowing fluorescence emission. The binding of a mature miRNA beacon to its target site can then be determined by measuring the emitted fluorescence. (B) The graph shows binding data for mi405 and mi1155 target sites within the DUX4 transcript, where mi405 bound two target sites (mi405 On-TS1 and mi405 On-TS2). The latter had a single mismatch within the 22 nt duplex and two terminal mismatches. mi1155 had strongest binding to its on-target site within DUX4 (Kd = 0.28 μM). The mi405 mature sequence bound its perfect target (mi405 On-TS1) with a Kd of 0.65 μM, with reduced binding at the second site (mi405 On-TS2; Kd = 1.20 μM). A negative control containing two additional mismatches within the mi405 On-TS2 duplex did not bind the mi405 molecular beacon (mi405 neg. ctrl TS). The molecular beacon signal expressed in relative fluorescence units (RFU) was subtracted from background fluorescent signal and used to determine the binding affinity (Kd), which is the binding site concentration (μM) required to reach half of maximum fluorescence. Data are displayed as means with error bars representing SD. (C) Putative off-target sites for mi405 and mi1155 in the indicated transcripts, as determined by PITA analysis of transcripts (CXCL11, C1QTNF1, LAMP3, and GBP4) that were significantly reduced in DUX4-negative human myoblasts expressing mi405 or mi1155 (specific sites are listed in Materials and Methods). The mi405 and mi1155 molecular beacons showed no binding affinity to any putative off-target sites. For cost and efficiency, the molecular beacon-binding assay was performed using DNA oligonucleotides. To mimic G:U base pairing that occurs in RNA:RNA duplexes, we generated RNA “mimic” bases in the miRNA:off-target site pair, such that A:T base pairing (pairing with two hydrogen bonds) was introduced, replacing the “G” nucleotide with an “A” nucleotide whenever the “G” is facing a “T.” These changes are indicated by gray-shaded nucleotides. miRNA:off-target site pairs are represented as two annealing strands. The top strand represents the target site, and the bottom strand represents the mature miDUX4 sequence.
Saline injections served as the controls, and AAV6.U6.mi405 or 1155 vectors were delivered at $3 \times 10^{10}$, $1 \times 10^{11}$, or $1.5 \times 10^{12}$ DRP. Mice were harvested at 3 weeks post-injection ($n = 2$ per dose per treatment), 6 and 12 weeks post-injection ($n = 3$ at $1 \times 10^{11}$ DRP per treatment), and 5 months post-injection ($n = 5$ per dose per treatment). All mouse procedures were performed following guidelines approved by the Institutional Animal Care and Use Committee (IACUC) at the Research Institute at Nationwide Children’s Hospital.

**Histology and Comparative Pathology**

Dissected TA muscles were placed in O.C.T. Compound (Tissue-Tek) and frozen on liquid nitrogen-cooled isopentane. Cryosections were cut at 10 μm and then stained with H&E following standard protocols. Dissected diaphragm, kidney, liver, heart, spleen, testis, and lung (needle perfused) were all post-fixed in 10% neutral buffered formalin for 48 hr and then processed, paraffin-embedded, cut, and stained with H&E-stained at the Nationwide Children’s Hospital Morphology Core Laboratory. TA muscles were analyzed by a blinded neuropathologist, and all other tissues were analyzed at The Ohio State University Comparative Pathology & Mouse Phenotyping Shared Resource.

**mi405 qPCR Assay**

The mi405 qPCR protocol was designed on the basis of methods previously described. Briefly, RNA was extracted using the total RNA protocol for the mirVana miRNA Isolation Kit (Ambion) from 25 50 μm cryosections of indicated TA muscles. cDNA was generated using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using a mix of random hexamer primers and 200 nM of the stem-loop forming primer ($5’$-GTC GTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGA $3’$). A custom TaqMan assay (Applied Biosystems) including 1.5 μM of forward primer ($5’$-CGGCCCCAAACCGATCT GAATC-3’), 0.7 μM of reverse primer ($5’$-GTCCAGGTTCCGA GTTCCAG-3’), and 0.2 μM of mi405 probe ($5’$-6FAM-ATACGAGTG GCCAGTATCCGACTGGATACGA-3’), was then run using the CFX Connect Real Time system apparatus (Bio-Rad). RPL13 (Mm02526700_g1; Applied Biosystems) served as the reference gene, and normalized expression $(\Delta \Delta Cq)$ was calculated relative to the lowest viral dose per experiment ($2 \times 10^{10}$ DRP for I.m. and $3 \times 10^{10}$ DRP for ILP).

**RNA-Seq and Off-Target Analysis**

Human immortalized myoblasts were transplanted with an AAV proviral plasmid expressing U6.mi405, U6.1155, or control plasmid pCiNeo using the Human Dermal Fibroblast Nucleofector Kit (Amaxa). RNA preparation, library construction, quality control, and sequencing were performed as previously described. pCiNeo controls were previously described as simultaneous experiments were run together using the same control group. Gene expression changes with fold change of $\pm 2.00$ and p values < 0.05 compared with controls were considered significant. These genes were then analyzed for miUX4 seed matching, and the predicted identity of all off-target sites in every off-target gene using two different prediction programs: siSPOTR and the PITA prediction algorithm.

RNA-seq was performed by the Biomedical Genomics Core of the Research Institute at Nationwide Children’s Hospital, Columbus, Ohio. Raw data files for the RNA-seq data are deposited at https://www.ncbi.nlm.nih.gov/sra/SRP127959 (SRA: SRP127959).

**Molecular Beacon-Binding Assay**

Mature DNA sequences of mi405 and mi1155 complementary to their cognate target sites were designed and used as previously described. A 6FAM fluorophore and a Zen Black Hole Quencher (ZenBHQ) were added at the 5’ and 3’ ends, respectively. The DNA molecular beacons were synthesized (Integrated DNA Technologies), and each molecular beacon had a density close to 3 OD and was purified using high-performance liquid chromatography (HPLC). The binding assay was performed as previously described, with some modifications. The binding assay was performed using the CFX Connect Real Time system apparatus. After mixing the molecular beacon and target site, the binding was initiated with a denaturation step at 95°C for 3 min, followed by an annealing step at 37°C for 10 min. The fluorescence was measured at the end of the annealing step. The relative fluorescent signal (relative fluorescence units [RFU]) was subtracted from background fluorescent signal and fit to a one-site-specific binding Hill slope equation that was used to determine the binding affinity ($K_d$). The mi405 and mi1155 molecular beacons were used at a constant concentration of 200 nM, and the constant parameter ($K_d$) was determined by increasing the concentration of the cognate target sites. $K_d$ is the binding site concentration (nM) required to reach half of the maximum fluorescence and represents binding affinity. The smaller the $K_d$ value, the greater the binding affinity of the miRNA molecular beacon is for its target site. We tested binding of off-target genes identified by RNA-seq (Table 2) and queried PITA and siSPOTR to identify transcripts with putative binding sites for mi405 and mi1155. We modified our molecular beacon assay by using DNA oligos designed to mimic G:U base pairing (two hydrogen bonds) that occurs in RNA:RNA duplexes. To mimic RNA:RNA base pairing in the miRNA-off-target site pair, A:T base pairing (pairing with two hydrogen bonds) was introduced, replacing the “G” nucleotide with an “A” nucleotide whenever the “G” is facing a “T.”

Predicted target sites are indicated as follows. mi405 On-TS1: on-target site on DUX4 open reading frame (ORF) at position 405; mi405 On-TS2: second on-target site on DUX4 ORF at position 193; and mi1155 On-TS: on-target site on DUX4 ORF at position 1155. The remaining annealing strands represent pairing of mi405 or mi1155 to their off-target sites. CXCL11 Off-TS1: mi405 off-target site on CXCL11 ORF at position 28; CXCL11 Off-TS2: mi405 off-target site on CXCL11 3’ UTR at position 82 from the beginning of 3’ UTR; CIQTNF1 Off-TS1: mi405 off-target site on CIQTNF1 ORF at position 21; CIQTNF1 Off-TS2: mi405 off-target site on CIQTNF1 3’ UTR at position 1494 from the beginning of 3’ UTR; LAMP3 Off-TS1: mi1155 off-target site on LAMP3 ORF at position 1310; LAMP3 Off-TS2: mi1155 off-target site on LAMP3 3’ UTR at
position 663 from the beginning of 3’UTR; GBP4 Off-TS1: mi1155 off-target site on GBP4 ORF at position 1466; GBP4 Off-TS2: mi1155 off-target site on GBP4 3’ UTR at position 3181 from the beginning of 3’UTR; mi1155 Off-TS1: mi1155 off-target site on DUX4 ORF at position 1194; mi1155 Off-TS2: mi1155 off-target site on DUX4 ORF at position 767; mi1155 Off-TS3: mi1155 off-target site on DUX4 3’ UTR at position 2050 from the beginning of 3’UTR; C1QTNF1 Off-TS3: mi1155 off-target site on C1QTNF1 ORF at position 19; C1QTNF1 Off-TS4: mi1155 off-target site on C1QTNF1 3’ UTR at position 1495 from the beginning of 3’UTR.

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Results, four figures, and three tables and can be found with this article online at https://doi.org/10.1016/j.omtm.2017.12.005.

AUTHOR CONTRIBUTIONS
L.M.W. designed and performed all mouse experiments and necropsies (except ILP surgeries), designed and performed qPCR assays, and contributed to western blots, RNA-seq experiments, and analysis. L.M.W. also created figures and legends and wrote the Materials and Methods section of the paper. N.Y.S. designed and performed the molecular beacon assay and created figures, legends, and methods with the assayed data. N.K.P. and J.S.D. cloned and tested the new miDUX4s in vitro. N.K.P. generated a supplemental figure and table with in vitro data. A.M.F. produced and titrated all AAV vectors. J.O.E. contributed to RNA-seq experiments. D.A.G. and L.R.R.-K. performed ILP surgeries and contributed to experimental design. A.C.H. created the algorithm used to identify new candidate miDUX4s. Z.S. was the pathologist who analyzed TA muscle histology. S.Q.H. conceptualized and obtained funding for the project, designed the miRNA predictor criteria, contributed to data analysis, and wrote the manuscript. All authors contributed to refining and editing the manuscript.

ACKNOWLEDGMENTS
This research and salaries for co-authors were supported by the FSHD Global Research Foundation (to S.Q.H.); the Chris Carrino Foundation (to S.Q.H. and J.O.E.); Friends of FSH Research (to J.O.E.); the FSH Society (grant FSHS-82015-02 to J.O.E. and FSHS-22016-05 to N.Y.S.); the NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Center of Research Translation in Muscular Dystrophy Therapeutic Development grant 1P50AR070604-01 (to S.Q.H. and L.R.R.-K.); NIAMS grant 1R01AR062123-05 (to S.Q.H.); National Institute of Neurological Disorders and Stroke (NINDS) Translational Program grant 1R21NS078327 (to S.Q.H.); and the University of Massachusetts Medical School Wellstone Center for FSHD (grant SU54HD060848-10). We thank the Comparative Pathology and Mouse Phenotyping Shared Resource, Department of Veterinary Biosciences, and the Comprehensive Cancer Center, The Ohio State University, supported in part by National Cancer Institute (NCI) grant P30 CA016658 and The Ohio State University Center for Clinical and Translational Science (CCTS) (Clinical and Translational Science Award [CTSA] grant UL1TR0017070). We thank Peter White, Amy Wetzel, and James Fitch of the Biomedical Genomics Core of the Research Institute at Nationwide Children’s Hospital for their help with RNA-seq data.

REFERENCES